What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2351.png

 

Surgical Pain

 

Diclofenac used in the treatment and management of acute and chronic pain associated with inflammatory conditions.1

Frame 427318815.png

It also has analgesic properties and antipyretic effects.1

Diclofenac employs its action by inhibiting the activity of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) by inhibiting the synthesis of prostanoids such as prostaglandin-E2 (PGE2), prostacyclins, and thromboxanes, which are essential components of the inflammatory and nociceptive response.1

Frame 427318816.png

Traditionally, two isoforms of COX are known, COX-1 and COX-2, on which diclofenac has inhibitory effects.2

Studies have also elucidated the benefits of using diclofenac post-operatively to reduce the need for rescue analgesia in patients after surgery.1

 

 

Our Products

 

Frame 427318595.png
Voltaren 75mg/3ml ampoules
Frame 427318594.png
Voltaren SR 100mg film-coated tablets
Frame 427318593.png
Cataflam 50mg sugar-coated tablets
Frame 427318596.png
Cataflam 75mg/3ml solution for injection

References

  1. Alfaro RA, Davis DD.STATPEARLS, Diclofenac; Available at: https://www.ncbi.nlm.nih.gov/books/NBK557879/ , last accessed: 15/5/2025..

  2. Akbulut N, Üstüner E, Atakan C, et al. Comparison of the effect of naproxen, etodolac and diclofenac on postoperative sequels following third molar surgery: a randomised, doubleblind, crossover study. Med Oral Patol Oral Cir Bucal. 2014;19(2):e149‐56.

Approved by Egyptian Drug Authority: HF0082OA4731/092025. Invalidation date: 01/09/2027.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg

Surgery QR Code

HF0082OA4731/092025
01/09/2027

 

        

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting